Domestic pharmaceutical firms keen to enter into antidiabetic market

As the patent of Handok-Aventis Pharma's Amaryl (glimepiride) is already expired and its post-surveillance system will be completed in July of next year, a number of domestic firms are on the lookout for potential revenue in the domestic antidiabetic market.

Market observers say that Korea's antidiabetic market size is estimated at 130 billion won and is expected to grow by more 20 percent a...